While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jkobTn8
via IFTTT
0 comments:
Post a Comment